A multi-omic study reveals BTG2 as a reliable prognostic marker for early-stage non-small cell lung cancer

Here we investigate whether a cancer-speci fi c footprint can be revealed by investigating circulating in fl ammatory markers in patients with non-small cell lung cancer

Early detection of disseminated tumor cells (DTCs) in lymph nodes could potentially enable identification of subcategories of patients with high risk of disease relapse.. Method:

Independent and Tissue Specific Prognostic Impact of miR-126 in Non-Small Cell Lung Cancer: Co-expression with Vascular Endothelial Growth Factor-A Predicts Poor Survival..

Conclusion: We have shown that combined ↑ cancer and ↑ stromal cell CXCL16 expression is an independent positive prognostic factor in NSCLC.. Further studies are warranted to

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan

Two human NSCLC cell lines with endogenous expression of PAX6 were transfected with either PAX6 siRNA or scrambled control siRNA, incu- bated for 48 hours, lysed and analysed

Lee, Early treatment volume reduction rate as a prognostic factor in patients treated with chemoradiotherapy for limited stage small cell lung cancer, Radiation oncology journal